Forte Biosciences Inc
NASDAQ:FBRX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Sharingtechnology Inc
TSE:3989
|
JP |
|
Total Brain Ltd
ASX:TTB
|
AU |
|
TSS Inc
OTC:TSSI
|
US |
|
D
|
Deccan Cements Ltd
NSE:DECCANCE
|
IN |
|
Intermestic Inc
TSE:262A
|
JP |
|
Remgro Ltd
OTC:RMGOF
|
ZA |
|
B
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
IN |
|
Arafura Resources Ltd
ASX:ARU
|
AU |
Forte Biosciences Inc
Research & Development
Forte Biosciences Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
Research & Development
-$41.7m
|
CAGR 3-Years
-111%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-9%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Research & Development
-$9.1B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-8%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Research & Development
-$5.7B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Research & Development
-$7.2B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-6%
|
|
|
Exact Sciences Corp
NASDAQ:EXAS
|
Research & Development
-$523m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-31%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Research & Development
-$3.9B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-15%
|
|
Forte Biosciences Inc
Glance View
Forte Biosciences, Inc. is a clinical stage biopharmaceutical company focused on dermatology. The company is headquartered in Torrance, California and currently employs 5 full-time employees. The company went IPO on 2017-04-13. The firm is focused on its lead product candidate, FB-401, which is a topical live biotherapeutic for the treatment of inflammatory skin diseases, including pediatric and adult patients with atopic dermatitis (AD). FB401 was developed in collaboration with the National Institutes of Health (NIH), and the National Institute of Allergy and Infectious Diseases (NIAID). FB-401 has completed Phase I/II a testing in adult and pediatric patients with atopic dermatitis.
See Also
What is Forte Biosciences Inc's Research & Development?
Research & Development
-41.7m
USD
Based on the financial report for Sep 30, 2025, Forte Biosciences Inc's Research & Development amounts to -41.7m USD.
What is Forte Biosciences Inc's Research & Development growth rate?
Research & Development CAGR 10Y
-9%
Over the last year, the Research & Development growth was -114%. The average annual Research & Development growth rates for Forte Biosciences Inc have been -111% over the past three years , 2% over the past five years , and -9% over the past ten years .
